The invention provides novel, substituted 3-arylamino pyridine compounds(I) pharmaceutically acceptable salts, solvates and prodrug compounds thereof,wherein W, R1, R2, R9, R10, R11, R12, R13, R14 are as defined in the specification.Such compounds are MEK inhibitors and useful in the treatment of hyperproliferativediseases, such as cancer, restenosis and inflammation. Also disclosed is theuse of such compounds in the treatment of hyperproliferative diseases in mammals,especially humans, and pharmaceutical compositions containing such compounds.
